Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123764 | 0.92 | PTGS1 (0.58) | ALDH1A1PTGS1TDP1HTTSMN1; SMN2 | |
| SCHEMBL8636829 | 0.89 | PTGS1 (0.54) | ALDH1A1PTGS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30345552 | 0.88 | PTGS1 (0.56) | ALDH1A1PTGS1TDP1HTTSMN1; SMN2 | |
| SCHEMBL11063307 | 0.88 | PTGS1 (0.56) | ALDH1A1PTGS1TDP1HTTSMN1; SMN2 | |
| SCHEMBL13183668 | 0.87 | ALDH1A1 (0.59) | ALDH1A1PTGS1TDP1HTTL3MBTL1 | |
| SCHEMBL765113 | 0.86 | PTGS1 (0.66) | ALDH1A1PTGS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30358257 | 0.86 | PTGS1 (0.66) | ALDH1A1PTGS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15849013 | 0.86 | PTGS1 (0.55) | ALDH1A1PTGS1TDP1HTTSMN1; SMN2 | |
| SCHEMBL14020499 | 0.85 | SMN1; SMN2 (0.58) | ALDH1A1PTGS1HTTSMN1; SMN2MEN1 | |
| SCHEMBL12260873 | 0.84 | PTGS1 (0.50) | ALDH1A1PTGS1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020216071-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20120160317-A1 | POLYIMIDE POLYMER SOLUTION, POLYIMIDE POLYMER, TRANSPARENT FILM, DISPLAYING DEVICE AND SOLAR CELL | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | ALDH1A1 779/4885PTGS1 2958/4885TDP1 4266/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | ALDH1A1 779/4885PTGS1 2958/4885TDP1 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.